Results

Total Results: 77 records

Showing results for "stage".

21. CDS Connect Implementation Guide Draft (doc file)
    cds.ahrq.gov/sites/default/files/cds/artifact/18/Implementation%20Guide_USPSTF%20Statin%20Use%20for%20the%20Primary%20Prevention%20of%20CVD%20in%20Adults_Final.docx
    October 01, 2017 - Exclude patients with end-stage renal disease and patients undergoing dialysis. 4. … 11.79 190 45                 +           TRUE TRUE End Stage … Work Group recommendation based on their medical expertise) Verify completeness Diagnosis of End Stage

22. CDS Connect Implementation Guide Draft (doc file)
    cds.ahrq.gov/sites/default/files/cds/artifact/21/Implementation%20Guide_Statin%20Therapy%20for%20the%20Prevention%20and%20Treatment%20of%20CVD%20eCQM_Final.docx
    October 01, 2017 - medications, who are receiving palliative care, who have hepatic disease or insufficiency, who have end-stage … Value sets needed to be established for computable definitions of ASCVD, end-stage renal disease, hepatic … Patients with end-stage renal disease (ESRD).

23. May-2017-Cholesterol-Wg-Notes (doc file)
    cds.ahrq.gov/sites/default/files/workgroups/236/may-2017-cholesterol-wg-notes.docx
    January 01, 2017 - Lookback Periods, and Notifications for the USPSTF Artifacts CAMH provided an update on the current stage

24. Pain Management Summary Clincial Decision Support Toolkit For Repository (xls file)
    cds.ahrq.gov/sites/default/files/cds/artifact/476/Pain%20Management%20Summary%20Clincial%20Decision%20Support%20Toolkit_for%20Repository.xlsx
    January 01, 2003 - failure, unspecified 313092 Sorbitol 700 MG/ML Oral Solution N18.1 Chronic kidney disease, stage … 2 (mild) 313863 Bisacodyl 5 MG Rectal Suppository N18.3 Chronic kidney disease, stage 3 (moderate … ) 314087 Magnesium Hydroxide 240 MG/ML Oral Suspension N18.4 Chronic kidney disease, stage 4 … (severe) 314113 Magnesium Oxide 200 MG Oral Tablet N18.5 Chronic kidney disease, stage 5 … Hydroxide 200 MG / Magnesium Hydroxide 200 MG / Simethicone 20 MG Chewable Tablet N18.6 End stage

25. Pain Management Summary Clincial Decision Support Toolkit For Repository 0 (xls file)
    cds.ahrq.gov/sites/default/files/cds/artifact/476/Pain%20Management%20Summary%20Clincial%20Decision%20Support%20Toolkit_for%20Repository_0.xlsx
    January 01, 2003 - failure, unspecified 313092 Sorbitol 700 MG/ML Oral Solution N18.1 Chronic kidney disease, stage … 2 (mild) 313863 Bisacodyl 5 MG Rectal Suppository N18.3 Chronic kidney disease, stage 3 (moderate … ) 314087 Magnesium Hydroxide 240 MG/ML Oral Suspension N18.4 Chronic kidney disease, stage 4 … (severe) 314113 Magnesium Oxide 200 MG Oral Tablet N18.5 Chronic kidney disease, stage 5 … Hydroxide 200 MG / Magnesium Hydroxide 200 MG / Simethicone 20 MG Chewable Tablet N18.6 End stage

26. November 2020 CDS Connect Work Group Call (pdf file)
    cds.ahrq.gov/sites/default/files/workgroups/1236/CDS_Connect_WG_Nov2020_Slides.pdf
    December 01, 2020 - significance in terms of confidence in authenticity, reliability, and trustworthiness, integrity, and stage

27. Statin Use for the Primary Prevention of CVD in Adults: Patient-Facing CDS Intervention (pdf file)
    cds.ahrq.gov/sites/default/files/cds/artifact/1056/Implementation%20Guide_Statin%20Use%20for%20CVD%20Prevention%20in%20Adults_Patient%20Facing%20CDS%20Intervention_Final.pdf
    September 01, 2019 - statement; therefore, is listed as an exclusion); currently pregnant or breastfeeding; a diagnosis of end stage … End stage renal disease (ESRD), end stage renal disease encounter, dialysis procedure, and dependence … Patient not included because their 10-Year risk score is less than 10% • Patient excluded due to end stage … ‘active' OR 'relapse’ (see https://www.hl7.org/fhir/DSTU2/valueset-condition- clinical.html) End Stage … present 38 Data Element Inclusion (I) vs Exclusion (X) FHIR Resource Required Elements End Stage

28. Apr-2017-Cholesterol-Wg-Notes (doc file)
    cds.ahrq.gov/sites/default/files/workgroups/231/apr-2017-cholesterol-wg-notes.docx
    January 01, 2017 - . · One system displays a best practice alert and the provider can click on ‘Accept’ to stage the order

29. USPSTF Aspirin Therapy for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer (pdf file)
    cds.ahrq.gov/sites/default/files/cds/artifact/26/Implementation%20Guide_Aspirin%20Therapy%20for%20the%20Prevention%20of%20CVD%20and%20CRC_final.pdf
    January 01, 2020 - Patient has end-stage renal disease. e. Patient is on another anticoagulant. f. … this artifact can follow the activities described below to enhance this artifact to the structured stage … bleed OR diagnosis of active GI ulcers OR diagnosis of bleeding disorders OR diagnosis of end stage

30. USPSTF Aspirin Therapy for Primary Prevention of CVD and CRC (April 2021) (pdf file)
    cds.ahrq.gov/sites/default/files/cds/artifact/26/Implementation%20Guide_Aspirin%20Therapy%20for%20the%20Prevention%20of%20CVD%20and%20CRC_final_2.pdf
    April 01, 2021 - Patient has end-stage renal disease. e. Patient is on another anticoagulant. f. … follow the activities described in the following section to enhance this artifact to the structured stage … bleed OR diagnosis of active GI ulcers OR diagnosis of bleeding disorders OR diagnosis of end stage

31. CDS Connect Implementation Guide Draft (doc file)
    cds.ahrq.gov/sites/default/files/cds/artifact/26/Implementation%20Guide_USPSTF%20Aspirin%20Therapy%20for%20the%20Prevention%20of%20CVD%20and%20CRC_Final.docx
    October 01, 2017 - Patient has end-stage renal disease. e. Patient is on another anticoagulant. f. … Figure 1: CDS Artifact Maturity Process To continue the maturation of this artifact to the structured stage

32. CDS Artifact Enhancement Based on Pilot Implementation. Factors to Consider in Managing Chronic Pain: (pdf file)
    cds.ahrq.gov/sites/default/files/cds/artifact/476/EnhancementofCDSArtifact%20BasedonPilotImplementation10012018.pdf
    December 01, 2018 - Both organizations collaborated on refinements to the CDS during every stage of the partnership to improve … of accurate CDS interventions. 15 Enhancements that occurred during this stage

33. Occupational Factors Which Impact Diabetes, A Final Knowledge Resource Report (2015) (pdf file)
    cds.ahrq.gov/sites/default/files/cds/artifact/171/Occupational%20Factors%20which%20Impact%20Diabetes,%20%20A%20Final%20Knowledge%20Resource%20Report%20(2015).pdf
    January 01, 2015 - Permissible follow-up questions at this stage differ from those at the pre-offer stage when an employer … The ADA prohibition on asking applicants about medical conditions at the pre-offer stage does not prevent

34. Statin Use for the Primary Prevention of CVD in Adults: Patient-facing CDS Intervention (April 2021) (pdf file)
    cds.ahrq.gov/sites/default/files/cds/artifact/1056/Implementation%20Guide_Statin%20Use%20for%20CVD%20Prevention%20in%20Adults_Patient%20Facing%20CDS%20Intervention_Final_1.pdf
    April 01, 2021 - • A diagnosis of end stage renal disease (ESRD) or receiving dialysis therapy. … ESRD, end stage renal disease encounter, dialysis procedure, and dependence on dialysis as exclusions … verificationStatus is ‘confirmed’ clinicalStatus is ‘active,’ ‘relapse,’ or ‘recurrence’ (R4 only) End Stage … verificationStatus is ‘confirmed’ clinicalStatus is ‘active’ no abatement[x] attributes are present End Stage

35. CDS Connect - Year 1 Final Report (pdf file)
    cds.ahrq.gov/sites/default/files/reports/AHRQ_Final_Report_2017.pdf
    January 01, 2017 - In part, this means the inclusion of detailed artifact development resources will support early stage … CDS developers as well as end-stage CDS implementers and evaluators. … organizations that lack sufficient CDS, so the MITRE-developed CDS, even if it is at a Level 2 or early 3 stage

36. CDS Connect Implementation Guide Draft (doc file)
    cds.ahrq.gov/sites/default/files/cds/artifact/81/Implementation%20Guide_Longitudinal%20ASCVD%20Risk%20Assessment%20Tool%20for%20Updated%20Risk_Final_0.docx
    October 01, 2017 - Figure 1: CDS Artifact Maturity Process To continue the maturation of this artifact to the structured stage

37. CDS Connect Implementation Guide Draft (doc file)
    cds.ahrq.gov/sites/default/files/cds/artifact/76/Implementation%20Guide_Longitudinal%20ASCVD%20Risk%20Assessment%20Tool%20for%20Shared%20Decision%20Making_Final_0.docx
    October 01, 2017 - Figure 2: CDS Artifact Maturity Process To continue the maturation of this artifact to the structured stage

38. Implementation Guide: Aspirin Use to Prevent Cardiovascular Disease: Preventive Medication (pdf file)
    cds.ahrq.gov/sites/default/files/cds/artifact/26/2023_CDS_Connect_IG_Aspirin_Therapy.pdf
    January 01, 2023 - Patient has end-stage renal disease. e. Patient is on another anticoagulant. f. … 19 OR diagnosis of active GI ulcers OR diagnosis of bleeding disorders OR diagnosis of end stage

39. Implementation Guide: Aspirin Use to Prevent Cardiovascular Disease: Preventive Medication (pdf file)
    cds.ahrq.gov/sites/default/files/cds/artifact/26/2024_CDS_Connect_IG_Aspirin_Therapy.pdf
    January 01, 2024 - Patient has end-stage renal disease. e. Patient is on another anticoagulant. 6 f. … bleed OR diagnosis of active GI ulcers OR diagnosis of bleeding disorders OR diagnosis of end stage

40. Warfarin-Nsaids Mdia Implementation Guide (doc file)
    cds.ahrq.gov/sites/default/files/cds/artifact/1141/Warfarin-NSAIDs%20MDIA%20Implementation%20Guide.docx
    November 11, 2019 - Implementation Guide Warfarin - NSAIDs Prepared by: Eric Chou Under funding from AHRQ grants R21 HS023826 and R01 HS025984 MDIA publication No. 001 November 11, 2019 Disclaimer The findings and conclusions in this document are those of the author(s), who are responsible for its content, and do not necessarily represen…